| Year |
Citation |
Score |
| 2015 |
Hamid OH. A model-based markovian context-dependent reinforcement learning approach for neurobiologically plausible transfer of experience International Journal of Hybrid Intelligent Systems. 12: 119-129. DOI: 10.3233/His-150210 |
0.402 |
|
| 2014 |
Hamid OH. The role of temporal statistics in the transfer of experience in context-dependent reinforcement learning 2014 14th International Conference On Hybrid Intelligent Systems, His 2014. 123-128. DOI: 10.1109/HIS.2014.7086184 |
0.398 |
|
| 2012 |
Hamid OH. Modelling behavioral flexibiliy: A dual controller for a context-dependent reinforcement learning paradigm 13th Middle Eastern Simulation and Modelling Multiconference, Mesm 2012 - 3rd Gameon-Arabia Conference, Gameon-Arabia 2012. 63-67. |
0.359 |
|
| 2011 |
Glüge S, Hamid OH, Braun J, Wendemuth A. A markov model of conditional associative learning in a cognitive behavioural scenario Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 6686: 10-19. DOI: 10.1007/978-3-642-21344-1_2 |
0.442 |
|
| 2010 |
Hamid OH, Wendemuth A, Braun J. Temporal context and conditional associative learning. Bmc Neuroscience. 11: 45. PMID 20353575 DOI: 10.1186/1471-2202-11-45 |
0.496 |
|
| 2010 |
Glüge S, Hamid OH, Wendemuth A. A Simple Recurrent Network for Implicit Learning of Temporal Sequences Cognitive Computation. 2: 265-271. DOI: 10.1007/S12559-010-9066-Z |
0.508 |
|
| 2008 |
Hamid O, Wendemuth A, Braun J. Why are unrelated associations learned more rapidly in a consistent temporal order Perception. 37: 76-76. DOI: 10.1068/V080273 |
0.485 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2014 |
Hamid OH. Online tutor-student interaction could compensate the lack of motivational effects that characterize face-to-face learning 20th European Concurrent Engineering Conference 2014, Ecec 2014 - 10th Future Business Technology Conference, Fubutec 2014. 10-12. |
0.25 |
|
| 2011 |
Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine. 9: 204. PMID 22123319 DOI: 10.1186/1479-5876-9-204 |
0.148 |
|
| 2011 |
Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leukemia & Lymphoma. 52: 1474-80. PMID 21649541 DOI: 10.3109/10428194.2011.572265 |
0.142 |
|
| 2012 |
Thompson JA, Hamid O, Minor D, Amin A, Ron IG, Ridolfi R, Assi H, Berman D, Siegel J, Weber JS. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 73-7. PMID 22130164 DOI: 10.1097/CJI.0b013e31823735d6 |
0.129 |
|
| 2014 |
Hamid O, Ilaria R, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, et al. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. Cancer. 120: 2016-24. PMID 24676877 DOI: 10.1002/cncr.28635 |
0.127 |
|
| 2011 |
Ledezma B, Binder S, Hamid O. Atypical clinical response patterns to ipilimumab. Clinical Journal of Oncology Nursing. 15: 393-403. PMID 21810572 DOI: 10.1188/11.CJON.393-403 |
0.12 |
|
| 2014 |
Schwartzberg L, Hermann R, Flinn I, Flora D, Hsi ED, Hamid O, Shi P, Lin BK, Myrand SP, Nguyen TS, Dreyling M. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma. British Journal of Haematology. 166: 91-7. PMID 24673609 DOI: 10.1111/bjh.12853 |
0.119 |
|
| 2015 |
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology. PMID 26115796 DOI: 10.1016/S1470-2045(15)00083-2 |
0.118 |
|
| 2013 |
Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2: e23033. PMID 23483678 DOI: 10.4161/Onci.23033 |
0.115 |
|
| 2013 |
Puzanov I, Wolchok JD, Ascierto PA, Hamid O, Margolin K. Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases Expert Review of Dermatology. 8: 479-487. DOI: 10.1586/17469872.2013.835922 |
0.114 |
|
| 2012 |
Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunology, Immunotherapy : Cii. 61: 1019-31. PMID 22146893 DOI: 10.1007/s00262-011-1172-6 |
0.114 |
|
| 2009 |
Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5591-8. PMID 19671877 DOI: 10.1158/1078-0432.CCR-09-1024 |
0.114 |
|
| 2012 |
Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Jackson JR. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunology, Immunotherapy : Cii. 61: 733-7. PMID 22382362 DOI: 10.1007/s00262-012-1227-3 |
0.113 |
|
| 2014 |
Flaherty L, Hamid O, Linette G, Schuchter L, Hallmeyer S, Gonzalez R, Cowey CL, Pavlick A, Kudrik F, Curti B, Lawson D, Chapman PB, Margolin K, Ribas A, McDermott D, et al. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer Journal (Sudbury, Mass.). 20: 18-24. PMID 24445759 DOI: 10.1097/PPO.0000000000000024 |
0.113 |
|
| 2013 |
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine. 369: 134-44. PMID 23724846 DOI: 10.1056/Nejmoa1305133 |
0.112 |
|
| 2015 |
Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, et al. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 415-21. PMID 25411413 DOI: 10.1093/annonc/mdu529 |
0.111 |
|
| 2012 |
Ezra N, Hamid O, Behroozan D. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma. Dermatologic Surgery : Official Publication For American Society For Dermatologic Surgery [Et Al.]. 38: 1086-90. PMID 22563699 DOI: 10.1111/j.1524-4725.2012.02396.x |
0.108 |
|
| 2012 |
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The Lancet. Oncology. 13: 459-65. PMID 22456429 DOI: 10.1016/S1470-2045(12)70090-6 |
0.107 |
|
| 2009 |
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7412-20. PMID 19934295 DOI: 10.1158/1078-0432.Ccr-09-1624 |
0.107 |
|
| 2012 |
Ozao-Choy J, Carvajal RD, Hamid O. Ipilimumab for metastatic melanoma. Drugs of Today (Barcelona, Spain : 1998). 48: 381-93. PMID 22745924 DOI: 10.1358/dot.2012.48.6.1811777 |
0.106 |
|
| 2015 |
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 16: 522-30. PMID 25840693 DOI: 10.1016/S1470-2045(15)70122-1 |
0.103 |
|
| 2013 |
Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthy S, Wolchok JD. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immunity. 13: 7. PMID 23833564 |
0.101 |
|
| 2010 |
Boasberg P, Hamid O, O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Seminars in Oncology. 37: 440-9. PMID 21074058 DOI: 10.1053/j.seminoncol.2010.09.004 |
0.101 |
|
| 2014 |
Leung AM, Lee AF, Ozao-Choy J, Ramos RI, Hamid O, O'Day SJ, Shin-Sim M, Morton DL, Faries MB, Sieling PA, Lee DJ. Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels. Frontiers in Oncology. 4: 110. PMID 24904825 DOI: 10.3389/fonc.2014.00110 |
0.099 |
|
| 2010 |
Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immunity. 10: 9. PMID 20957980 |
0.097 |
|
| 2003 |
Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1498-504. PMID 12697873 DOI: 10.1200/Jco.2003.09.114 |
0.095 |
|
| 2015 |
Spitler LE, Boasberg P, O'Day S, Hamid O, Cruickshank S, Mesko S, Weber RW. Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma. American Journal of Clinical Oncology. 38: 61-7. PMID 25616203 DOI: 10.1097/COC.0b013e318287bbae |
0.095 |
|
| 2013 |
Forsyth CJ, Gomez-Almaguer D, Camargo JF, Eliadis PE, Crespo-Solis E, Pereira J, Gutierrez-Aguirre CH, Rivas-Vera S, Roberson S, Lin B, Smith NV, Hamid O. A multicenter, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas. Clinical Lymphoma, Myeloma & Leukemia. 13: 398-403. PMID 23770158 DOI: 10.1016/j.clml.2013.03.005 |
0.094 |
|
| 2014 |
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. The Lancet. Oncology. 15: 323-32. PMID 24508103 DOI: 10.1016/S1470-2045(14)70012-9 |
0.094 |
|
| 2014 |
Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2277-84. PMID 25210016 DOI: 10.1093/Annonc/Mdu441 |
0.094 |
|
| 2012 |
Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 379: 1893-901. PMID 22608338 DOI: 10.1016/S0140-6736(12)60398-5 |
0.093 |
|
| 2014 |
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 384: 1109-17. PMID 25034862 DOI: 10.1016/S0140-6736(14)60958-2 |
0.091 |
|
| 2014 |
Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. The Lancet. Oncology. 15: 954-65. PMID 25037139 DOI: 10.1016/S1470-2045(14)70301-8 |
0.088 |
|
| 2007 |
O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 110: 2614-27. PMID 18000991 DOI: 10.1002/cncr.23086 |
0.088 |
|
| 2016 |
Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26811525 DOI: 10.1200/JCO.2015.62.9345 |
0.087 |
|
| 2014 |
Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3697-704. PMID 25287827 DOI: 10.1200/JCO.2014.57.3535 |
0.086 |
|
| 2015 |
Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, et al. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2289-96. PMID 25695690 DOI: 10.1158/1078-0432.Ccr-14-1630 |
0.085 |
|
| 2012 |
O'Day SJ, Pavlick AC, Albertini MR, Hamid O, Schalch H, Lang Z, Ling J, Mata M, Reddy M, Foster B. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma. Investigational New Drugs. 30: 1074-81. PMID 21331745 DOI: 10.1007/s10637-011-9639-z |
0.085 |
|
| 2015 |
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1889-94. PMID 25667295 DOI: 10.1200/Jco.2014.56.2736 |
0.084 |
|
| 2015 |
Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, Chyla B, Jiang F, McKeegan E, Mostafa NM, Zhu M, Qian J, McKee M, Luo Y, Giranda VL, et al. Randomized Phase 2 Study Evaluating Veliparib (ABT-888) With Temozolomide in Patients With Metastatic Melanoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26202595 DOI: 10.1093/annonc/mdv308 |
0.084 |
|
| 2015 |
El Samad A, Hamid OH. The role of socio-economic disparities in varying the viewing behavior of e-learners 2015 5th International Conference On Digital Information and Communication Technology and Its Applications, Dictap 2015. 74-79. DOI: 10.1109/DICTAP.2015.7113174 |
0.083 |
|
| 2013 |
Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3205-11. PMID 23918947 DOI: 10.1200/JCO.2013.49.8691 |
0.083 |
|
| 2012 |
Postow MA, Hamid O, Carvajal RD. Mucosal melanoma: pathogenesis, clinical behavior, and management. Current Oncology Reports. 14: 441-8. PMID 22661391 DOI: 10.1007/s11912-012-0244-x |
0.081 |
|
| 2015 |
Dummer R, Daud A, Puzanov I, Hamid O, Schadendorf D, Robert C, Schachter J, Pavlick A, Gonzalez R, Hodi FS, Cranmer LD, Blank C, O'Day SJ, Ascierto PA, Salama AK, et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. Journal of Translational Medicine. 13: 2062. PMID 25779181 DOI: 10.1186/1479-5876-13-S1-O5 |
0.08 |
|
| 2012 |
Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 89-97. PMID 22130166 DOI: 10.1097/CJI.0b013e31823aa41c |
0.08 |
|
| 2015 |
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England Journal of Medicine. 372: 2521-32. PMID 25891173 DOI: 10.1056/NEJMoa1503093 |
0.079 |
|
| 2014 |
Carvajal RD, Hamid O, Antonescu CR. Selecting patients for KIT inhibition in melanoma. Methods in Molecular Biology (Clifton, N.J.). 1102: 137-62. PMID 24258978 DOI: 10.1007/978-1-62703-727-3_9 |
0.079 |
|
| 2013 |
Salih TM, Hamid O. Discrimination of four classes in Brain Computer Interface based on motor imagery Proceedings - 2013 International Conference On Computer, Electrical and Electronics Engineering: 'Research Makes a Difference', Icceee 2013. 418-422. DOI: 10.1109/ICCEEE.2013.6633974 |
0.078 |
|
| 2012 |
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England Journal of Medicine. 367: 1694-703. PMID 23020132 DOI: 10.1056/NEJMoa1210093 |
0.077 |
|
| 2011 |
Hamid O, Boasberg PD, Rosenthal K, O'Day SJ. Systemic treatment of metastatic melanoma: new approaches. Journal of Surgical Oncology. 104: 425-9. PMID 21858838 DOI: 10.1002/jso.22034 |
0.075 |
|
| 2016 |
McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fassò M, Wang YV, Zou W, Hegde PS, Fine GD, Powles T. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26755520 DOI: 10.1200/JCO.2015.63.7421 |
0.074 |
|
| 2014 |
Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3659-66. PMID 25267741 DOI: 10.1200/JCO.2013.54.8115 |
0.071 |
|
| 2005 |
Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5597-604. PMID 16110019 DOI: 10.1200/JCO.2005.08.091 |
0.071 |
|
| 2014 |
Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, et al. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4449-58. PMID 24958809 DOI: 10.1158/1078-0432.Ccr-14-0887 |
0.07 |
|
| 2013 |
Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1813-21. PMID 23535954 DOI: 10.1093/annonc/mdt107 |
0.07 |
|
| 2014 |
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515: 563-7. PMID 25428504 DOI: 10.1038/Nature14011 |
0.068 |
|
| 2013 |
Vermorken JB, Licitra L, Stöhlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, Hossain AM, Chang SC, Gauler TC. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer (Oxford, England : 1990). 49: 2877-83. PMID 23726971 DOI: 10.1016/j.ejca.2013.05.002 |
0.068 |
|
| 2012 |
Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC. Sunitinib therapy for melanoma patients with KIT mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1457-63. PMID 22261812 DOI: 10.1158/1078-0432.CCR-11-1987 |
0.066 |
|
| 2015 |
Hainsworth JD, Arrowsmith ER, McCleod M, Hsi ED, Hamid O, Shi P, Lin BK, Fayad LE. An open-label, randomized, phase 2 Study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- or high-riskdiffuse large B-cell lymphoma. Leukemia & Lymphoma. 1-11. PMID 25956042 DOI: 10.3109/10428194.2015.1045898 |
0.066 |
|
| 2015 |
Flaherty DC, Hoffner BW, Lau BJ, Hamid O, Faries MB. Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma. Journal of Surgical Oncology. PMID 26503563 DOI: 10.1002/jso.24078 |
0.064 |
|
| 2015 |
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, ... Hamid O, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine. 372: 2018-28. PMID 25891174 DOI: 10.1056/Nejmoa1501824 |
0.062 |
|
| 2014 |
Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1335-44. PMID 24418642 DOI: 10.1158/1078-0432.CCR-13-2436 |
0.06 |
|
| 2014 |
Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, ... ... Hamid O, et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2457-65. PMID 24634374 DOI: 10.1158/1078-0432.Ccr-13-3017 |
0.058 |
|
| 2012 |
Hamid O, Carvajal RD, Morton DL, Faries M. Unusual Melanomas Textbook of Uncommon Cancer. 691-708. DOI: 10.1002/9781118464557.ch51 |
0.057 |
|
| 2004 |
Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4456-62. PMID 15483017 DOI: 10.1200/JCO.2004.01.185 |
0.057 |
|
| 2013 |
Hamid O, Goldenberg G. Identifying patients at risk for recurrent or advanced BCC. Journal of Drugs in Dermatology : Jdd. 12: 1246-52; quiz 1253-4. PMID 24196332 |
0.056 |
|
| 2014 |
Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 73: 467-73. PMID 24390424 DOI: 10.1007/S00280-013-2372-X |
0.055 |
|
| 2014 |
Mesko SM, Rosenthal KJ, Boasberg PD, Hamid O. BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 24711550 DOI: 10.1200/JCO.2013.49.5622 |
0.052 |
|
| 2013 |
Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opinion On Biological Therapy. 13: 847-61. PMID 23421934 DOI: 10.1517/14712598.2013.770836 |
0.052 |
|
| 2006 |
Hamid O, O'Day S. Commentary on stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of metastases: A randomized controlled trial American Journal of Oncology Review. 5: 629-633. |
0.052 |
|
| 2013 |
Nasr A, Hamid O, Al-Ghamdi A, Allam G. Anti-malarial IgG subclasses pattern and FcγRIIa (CD32) polymorphism among pregnancy-associated malaria in semi-immune Saudi women. Malaria Journal. 12: 110. PMID 23517907 DOI: 10.1186/1475-2875-12-110 |
0.051 |
|
| 2013 |
Goldenberg G, Hamid O. Nonsurgical treatment options for basal cell carcinoma - focus on advanced disease. Journal of Drugs in Dermatology : Jdd. 12: 1369-78. PMID 24301238 |
0.048 |
|
| 2012 |
Schmidinger M, Szczylik C, Sternberg CN, Kania M, Kelly CS, Decker R, Hamid O, Faelker T, Escudier B. Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma. American Journal of Clinical Oncology. 35: 493-7. PMID 21654314 DOI: 10.1097/COC.0b013e31821cfc41 |
0.046 |
|
| 2012 |
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine. 366: 2455-65. PMID 22658128 DOI: 10.1056/Nejmoa1200694 |
0.044 |
|
| 2015 |
Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26392102 DOI: 10.1200/Jco.2015.63.2471 |
0.044 |
|
| 2013 |
Goldenberg G, Hamid O. Understanding BCC pathogenesis: treatment advancements and challenges. Journal of Drugs in Dermatology : Jdd. 12: 1110-20. PMID 24085046 |
0.044 |
|
| 2014 |
Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, Lynch HT, Von Hoff DD, Hamid O. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 2965-70. PMID 25392179 DOI: 10.1158/1055-9965.EPI-14-0654 |
0.044 |
|
| 2014 |
Nasr A, Allam G, Hamid O, Al-Ghamdi A. IFN-gamma and TNF associated with severe falciparum malaria infection in Saudi pregnant women. Malaria Journal. 13: 314. PMID 25124540 DOI: 10.1186/1475-2875-13-314 |
0.042 |
|
| 2007 |
Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 215-22. PMID 17200357 DOI: 10.1158/1078-0432.CCR-06-1450 |
0.041 |
|
| 2007 |
Hamid O. Identifying second language errors: How plausible are plausible reconstructions? Elt Journal. 61: 107-116. DOI: 10.1093/elt/ccm003 |
0.04 |
|
| 2004 |
Hamid O. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. Journal of the American Pharmacists Association : Japha. 44: 52-8. PMID 14965154 DOI: 10.1331/154434504322713237 |
0.036 |
|
| 2014 |
Hamid O. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors. Clinical Advances in Hematology & Oncology : H&O. 12: 782-4. PMID 25674719 |
0.032 |
|
| 2015 |
Hamid O, Rahim Z. Mechanical properties of carbonate formation and their influences on drilling and hydraulic fracture modeling Spe Middle East Oil and Gas Show and Conference, Meos, Proceedings. 2015: 607-617. |
0.027 |
|
| 2015 |
Trivedi MS, Hoffner B, Winkelmann JL, Abbott ME, Hamid O, Carvajal RD. Programmed death 1 immune checkpoint inhibitors Clinical Advances in Hematology and Oncology. 13: 858-868. |
0.027 |
|
| 2001 |
Ramadan QM, Hamid O, Lim KO. Steady flow visualization in a rigid model of the aortic bifurcation: application to atherosclerosis. Journal of Biological Physics. 27: 35-57. PMID 23345732 DOI: 10.1023/A:1011822423672 |
0.024 |
|
| 2008 |
Alexander W, O'Day S, Hamid O, Weber J. American Society of Clinical Oncology: Ipilimumab for melanoma P and T. 33: 403+425. |
0.023 |
|
| 2005 |
Hamid O, El Fiky L, El Arab LE, El Beltagy Y, Amin R. Small cell carcinoma of the larynx: a case report. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 133: 647. PMID 16213969 DOI: 10.1016/j.otohns.2005.03.078 |
0.022 |
|
| 2014 |
Alaiwy FH, Alaiwy MH, Hamid OH. A Gene Expression Programming approach for optimizing technical rules in the foreign exchange market 20th European Concurrent Engineering Conference 2014, Ecec 2014 - 10th Future Business Technology Conference, Fubutec 2014. 21-25. |
0.022 |
|
| 2013 |
Hamid O. Is IL-2 still indicated for melanoma and RCC? What a question to ask! Oncology (Williston Park, N.Y.). 27: 695, 701. PMID 23977765 |
0.021 |
|
| 2007 |
Hamid O, Pagnini PG, O'Day S. Newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: With one question answered, more have arisen American Journal of Hematology/ Oncology. 6: 131-133. |
0.02 |
|
| 2013 |
El Fiky L, Shoukry T, Hamid O. Pediatric parapharyngeal lesions: criteria for malignancy. International Journal of Pediatric Otorhinolaryngology. 77: 1955-9. PMID 24139512 DOI: 10.1016/j.ijporl.2013.09.010 |
0.02 |
|
| 2009 |
Mohammad S, Akbar D, Hamid O, Islam R. Institutional, economic and technical dimensions of choosing private tertiary education in Bangladesh: Lessons for australian universities Proceedings of the Ieee International Conference On Industrial Technology. DOI: 10.1109/ICIT.2009.4939722 |
0.019 |
|
| 2013 |
Hamid O, Liyes A, Bouabdallah A. Investigation of theflow around a circular cylinder submitted to rotational oscillation and periodical cross-section variation 20th International Congress On Sound and Vibration 2013, Icsv 2013. 1: 153-158. |
0.019 |
|
| 2003 |
Ramadan QM, Hamid O, Lim KO. Steady flow visualization in a rigid model of the aortic-renal junction: Application to atherosclerosis Physica Medica. 19: 295-303. |
0.017 |
|
| 2002 |
Jaafar MS, Hamid O, Khor CS, Yuvaraj RM. Preliminary studies of left ventricular wall thickness and mass of normotensive and hypertensive subjects using m-mode echocardiography. The Malaysian Journal of Medical Sciences : Mjms. 9: 28-33. PMID 22969315 |
0.017 |
|
| 1992 |
Hamid O, Jones DP, Lazare R, Wolowacz SE. The ocular bioavailability of tropical triamterene in the conscious rabbit by a non-invasive method Human and Experimental Toxicology. 11: 584-585. |
0.017 |
|
| 2006 |
Tagawa ST, Hamid O, Skinner E, Kumar P. Uncommon Cancers of the Prostate Textbook of Uncommon Cancer, Third Edition. 38-65. DOI: 10.1002/0470030542.ch4 |
0.015 |
|
| 2013 |
Abdelrahman A, Hamid O. Evaluation of linear filter kernel developed from ultrasound phantom image Proceedings - 2013 International Conference On Computer, Electrical and Electronics Engineering: 'Research Makes a Difference', Icceee 2013. 620-623. DOI: 10.1109/ICCEEE.2013.6634011 |
0.012 |
|
| 2015 |
Hamid O, Rahim Z, Harbi AK, Mohiuddin M, Ba-wazir OA. Geomechanical characterization of hydraulic fracture in tight carbonates due to depletion Spe Middle East Oil and Gas Show and Conference, Meos, Proceedings. 2015: 2688-2697. |
0.012 |
|
| 2015 |
Hamid O, Pensch M, Agis H. Release kinetics of prolyl hydroxylase inhibitors from collagen barrier membranes. Journal of Biomaterials Applications. 29: 1059-67. PMID 25326176 DOI: 10.1177/0885328214556158 |
0.012 |
|
| 2011 |
Abdelrahman A, Hamid O. Lesion boundary detection in ultrasound breast images 2011 1st Middle East Conference On Biomedical Engineering, Mecbme 2011. 320-323. DOI: 10.1109/MECBME.2011.5752130 |
0.012 |
|
| 1997 |
Minshall EM, Tscopoulos A, Yasruel Z, Wallaert B, Akoum H, Vorng H, Tonnel AB, Hamid O. Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis Pneumologie. 51: 1081. |
0.012 |
|
| 2013 |
Hamid O, El Hakim A, El Husseiny H, El Fiky L, Kamel S. Craniocaudal extension as an indication of surgical outcome in transsphenoidal surgery for pituitary adenomas. Indian Journal of Otolaryngology and Head and Neck Surgery : Official Publication of the Association of Otolaryngologists of India. 65: 231-5. PMID 24427652 DOI: 10.1007/s12070-011-0350-3 |
0.011 |
|
| 2015 |
Hamid O, Rahim Z, Alshakhs M, Mubarak A, Fisher K, Ba-wazir OA. Completion optimization for unconventional reservoir Spe Middle East Oil and Gas Show and Conference, Meos, Proceedings. 2015: 2424-2438. |
0.01 |
|
| 2008 |
Hamid O, El Fiky L, Hassan O, Kotb A, El Fiky S. Anatomic Variations of the Sphenoid Sinus and Their Impact on Trans-sphenoid Pituitary Surgery. Skull Base : Official Journal of North American Skull Base Society ... [Et Al.]. 18: 9-15. PMID 18592020 DOI: 10.1055/s-2007-992764 |
0.01 |
|
| 2001 |
Salim SM, Hamid O. Growth and characterization of lead sulfide films deposited on glass substrates Renewable Energy. 24: 575-580. DOI: 10.1016/S0960-1481(01)00044-1 |
0.01 |
|
| 2000 |
Hamid O, Tajuddin AA. Triamterene measurements in the aqueous humor of rabbits. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 16: 565-9. PMID 11132903 |
0.01 |
|
| Hide low-probability matches. |